Author:
Davar Diwakar,Kirkwood John M.
Reference87 articles.
1. A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma (2013) 2013 ASCO annual meeting|abstracts|meeting library [internet]. Cited 24 May 2016. Available from:
http://meetinglibrary.asco.org/content/115887-132
2. Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI et al (2017) Phase III randomized study of 4 weeks of high-dose interferon-α-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol 35(8):885–892
3. Agrawal S, Kane JM, Guadagnolo BA, Kraybill WG, Ballo MT (2009) The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 115(24):5836–5844
4. AJCC – American Joint Committee on Cancer [Internet]. Cited 24 May 2016. Available from:
https://cancerstaging.org/Pages/default.aspx
5. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2788